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Background
Eliciting broadly reactive neutralizing antibodies remains
a challenge in HIV-1 vaccine development, complicated
by variations in envelope (Env) subtype and structure,
and by the assays used for product down-selection.
Since a majority of new HIV-1 infections are subtype C
and considering the novel properties of C Envs, a C Env
(CO6980v0c22) from an acutely infected Tanzanian was
developed as a candidate HIV vaccine.
Methods
The CO6980v0c22 Env sequence was codon optimized
and a stable CHO cell line expressing gp145 was estab-
lished. Purified gp145 was adjuvanted in alum or lipid
A-liposomes, injected into New Zealand white rabbits
(4/group; 25 ug at weeks 0, 4, and 8), or BALB/c mice
(5/group; 10 ug in liposomes at weeks 0, 3, 6, 8). Anti-
body titers were assessed by ELISA and neutralizing
antibodies were measured against pseudoviruses in
TZM-bl cells or against infectious molecular clones
(IMC) in a PBMC assay.
Results
Secreted gp145 is a novel subunit with the full MPER
extended by three lysines. Unlike some gp140 subunits,
the 4E10 neutralizing monoclonal antibody (mAb) binds
to gp145. IgG1b12 binds weakly, VRC01 binds potently, as
does the V2-specific 697D mAb; the gp145 also binds to
alpha4beta7 receptor, as demonstrated by flow cytometry.
At week 10 post-immunization, rabbit sera showed strong
binding antibody titers to several Env antigens, including
the clade B V1V2gp70 scaffold protein. While neutraliza-
tion of the HIV-2 MPER-scaffold pseudovirus was nega-
tive, cross-clade neutralization was observed in both
rabbits and mice, against Tier 1 subtype B and C pseudo-
viruses, and against Tier 1 and Tier 2 IMC. Using EGS
cross-linking, it appears that the majority of the gp145
multimers are trimeric; this is currently under investiga-
tion using electron microscopy techniques.
Conclusion
These data indicate essential immunogenic features of a
novel acute C HIV-1 Env that warrants further testing
for potential clinical development.
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